Sep 17, 2018 8:00am EDT Ensysce Biosciences Receives Multi-Year NIDA Grant to Study and Deliver Opioid Overdose Protection
Sep 04, 2018 8:00am EDT Ensysce Biosciences to Present Novel TAP Opioid Technology at 7th Annual Gateway Investor Conference September 5, 2018
Jun 11, 2018 8:00am EDT Ensysce Biosciences to Participate in New Generation Analgesics Symposium at Annual Meeting of the College on Problems of Drug Dependence
Jan 29, 2018 8:00am EST Ensysce Biosciences Inc. Receives Fast Track Designation for PF614, BIO-MD™ Abuse Deterrent Extended Release Oxycodone Prodrug
Nov 06, 2017 8:00am EST Ensysce Biosciences Inc. to Present at Human Abuse Liability & Abuse-Deterrent Formulations Conference in Bethesda, Maryland on November 6th and 7th
Sep 25, 2017 8:00am EDT Ensysce Biosciences Inc. to Present at 11th Annual Pain and Migraine Therapeutic Summit in San Diego, CA on September 27, 2017
Jun 12, 2017 8:00am EDT Ensysce Biosciences Inc. Attending NIH Conference: Cutting Edge Science Meeting Series to End the Opioid Crisis: Development of Safe, Effective, Non-Addictive Pain Treatments
Apr 03, 2017 8:00am EDT Ensysce Biosciences Inc. Publishes Manuscript Describing the in Vitro Abuse Deterrence of Oxycodone Prodrug, PF614
Jan 02, 2017 1:12pm EST Ensysce Biosciences to present initial Phase 1 data on abuse deterrent opioid, PF614, at Biotech Showcase™ 2017.
Dec 01, 2016 2:00pm EST Ensysce Biosciences Inc. Initiates Phase 1 Clinical Trial to Study PF614, BIO-MD™ Prodrug of Oxycodone